Reliant AI

Meet Brielan Smiechowski, one of our incredible Strategic Engagement Managers at Reliant AI! You can learn more about Brielan's journey to a vibrant career in health and her contributions in our latest blog post. P.S. If you're feeling particularly inspired, you can join the team. We're hiring for a similar role in Berlin or London! 🔗 Find the link to the blog and our job postings in the comments below! #TeamSpotlight #LifeAtReliant #AI #LifeSciences

We're hiring a life sciences expert to join our team in Berlin (or London)! Read on to see why Sam Mardini joined Reliant AI and his path from commercial life sciences consulting to agentic AI. Our team would love to hear from you if you're interested in charting a similar path. #TalentTuesday #Hiring #Berlin #London #LifeSciences

Are your AI tools oversimplifying critical insights from scientific texts? 👀 You've likely encountered generalization bias in large language models (LLMs), and if the term is unfamiliar, that's perfectly fine. Generalization bias refers to the tendency of LLMs to oversimplify complex information or overlook crucial details in summaries, especially when precision is paramount. While many AI tools excel at general tasks, like clarifying an email, they often struggle with the exactitude required for screening and extracting data from scientific or technical texts. This presents a significant problem. Scientific evidence relies on precise language and industry-specific rhetoric. When an AI summarizes a scientific text incorrectly, it can lead to inaccurate inferences and, consequently, erode trust in the AI's output. At Reliant AI, we fine-tune our LLMs to deliver the linguistic precision that life sciences teams need, allowing them to focus on their research and analysis rather than correcting AI outputs. Our goal is to help teams screen and extract data more efficiently, empowering you to reach the crucial last mile of analysis with confidence. Read on to see how Reliant AI avoids generalization bias and empowers researchers and commercial teams in the life sciences. Link is below! #LifeSciences #AI #LLMs #GeneralizationBias

The Reliant AI team is growing. 🌱 We're seeking a Strategic Engagement Manager to join our Berlin or London office and support our EU/UK clients. If you have 2+ years of experience in life sciences consulting or commercial spaces and love driving customer success with SaaS solutions, we want to hear from you. You'll not only enable our customers to succeed, but you'll also represent the voice of the user within Reliant and collaborate closely cross-functionally to help guide the future of our product. 🔗 Apply in the comments! #Startups #Hiring #London #Berlin #LifeSciences

Exciting news for life sciences researchers! 🎉 We have some new features to make your workflows more efficient without quality compromises. New capabilities include: - Full PDF upload and analysis - Clinical trial search by MoA - Natural language search for PubMed - Conference abstract search Learn more and see Reliant AI in action using the link below. #LifeSciences #ResearchTools #AIinScience #Biotech

Last night, Golden Ventures' Plated series ventured to Montréal during Startupfest to bring together an exceptional group of life sciences founders and industry leaders for a candid and insightful dinner and fireside chat on the "future of drug development" that reflected the depth and passion of one of the most integral and innovative communities within the Canadian technology ecosystem 🇨🇦 🧪 💊 🧬 A huge thank you to our distinguished guests and speakers, Shreyas Becker (Head of AI & Data @ Sanofi), Naheed Kurji (Former President of Recursion Canada & CEO / Co-founder @ Cyclica), Anthony Mouchantaf (CEO / Co-founder @ Biossil) and Marc G. Bellemare (CSO / Co-founder @ Reliant AI) As you can imagine, the conversation journeyed wide and deep, exploring key topics like: 1. The real impact and implementation successes and challenges of AI across the drug development value chain, from R&D to manufacturing and commercialization 2. The evolving regulatory landscape and how its construction shapes innovation and operational agility 3. The mapping of incentives across stakeholders and examined how aligning them from first principles can drive optimal patient outcomes 4. Perspectives on capital formation, fundraising strategies, and the realities of building and scaling in today’s life sciences environment We were incredibly energized by the openness and ingenuity of this community, and grateful to everyone who contributed to such a thoughtful, forward-looking discussion. The future of drug development belongs to those willing to challenge assumptions, embrace new technologies and keep patient outcomes at the heart of innovation! Thanks to all who attended for making the evening unforgettable, and a special thanks to our sponsors for the evening: Osler, Hoskin & Harcourt LLP (Jean-Nicolas Delage , Calvin Leung), TD Innovation Partners (Anthony Sturgeon, Mark Kiyonaga), Amazon Web Services (AWS), (Andry Tanusdjaja, CPA, CFA, Thomas Bouhon) cc: Golden Ventures, Julia Baird, Matt Golden, Ameet Shah, Alison Kaizer, Jamie Rosenblatt, Bert Amato, Vincent Xue

Paula Mello Ferber, who brings more than a decade of experience in life sciences and GTM, reflected on her experience hiring for GTM roles at Reliant AI. Her blog post shares insights for both candidates and hiring managers. Bonus: she is giving 10 career advice sessions to professionals looking for roles in GTM in PharmaTech.

Reliant AI is hiring! We’re looking for talented individuals to join our technical teams in Montreal and Berlin. At Reliant AI, we’re proud of our diverse, global team. Our colleagues come from all over the world and together speak more than 11 languages. Expect a team that brings fresh ideas and passionate perspectives, inspiring and challenging us every day. Check out the link in the comments to get more information. #TalentTuesday #Startups #Hiring

Artificial Intelligence is changing how we solve problems, both big and small. But to make the most of it, it helps to understand the two main ways AI "thinks." In our latest blog post, we feature a recent lecture from our CEO, Karl Moritz Hermann, on System 1 and System 2 AI, drawing parallels between Daniel Kahneman’s "Thinking, Fast and Slow" and what Reliant is building every day. Read more here: https://lnkd.in/gBRJg3SH

Halfway through 2025, we’re seeing our predictions take shape: - More teams are opting to buy, rather than build, focusing on partnering with scalable solutions that provide engineering support - AI is moving beyond discovery into trials, compliance, and commercial operations - With Insilico Medicine’s Rentosertib advancing through the pipeline, the reality of patients receiving clinical benefit from AI-designed drugs is closer and closer. Swipe through for a look at what’s unfolding and how Reliant helps teams stay ahead. How does this apply to your work? Drop a comment and let’s connect.